0000905148-23-000511.txt : 20230726 0000905148-23-000511.hdr.sgml : 20230726 20230726181455 ACCESSION NUMBER: 0000905148-23-000511 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210223 FILED AS OF DATE: 20230726 DATE AS OF CHANGE: 20230726 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: O'Kane Kieran CENTRAL INDEX KEY: 0001828131 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39659 FILM NUMBER: 231114842 MAIL ADDRESS: STREET 1: 2970 WILDERNESS PLACE STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIODESIX INC CENTRAL INDEX KEY: 0001439725 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 203986492 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2970 WILDERNESS PLACE STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 303-417-0500 MAIL ADDRESS: STREET 1: 2970 WILDERNESS PLACE STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 4 1 form4.xml X0508 4 2021-02-23 0001439725 BIODESIX INC BDSX 0001828131 O'Kane Kieran 2970 WILDERNESS PLACE SUITE 100 BOULDER CO 80301 true Chief Commercial Officer false Stock Options (Right to buy) 20.67 2021-02-23 4 A 0 25599 0 A 2031-02-22 Common Stock 25599 25599 D Stock Options (Right to buy) 20.67 2021-02-23 4 A 0 31055 0 A 2031-02-22 Common Stock 31055 31055 D Stock Options (Right to buy) 20.67 2023-07-24 4 D 0 25599 D 2031-02-22 Common Stock 25599 0 D Stock Options (Right to buy) 20.67 2023-07-24 4 D 0 31055 D 2031-02-22 Common Stock 31055 0 D Stock Options (Right to buy) 1.2 2023-07-24 4 A 0 11564 A 2033-07-23 Common Stock 11564 11564 D This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021. This option was fully vested as of the grant date. On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. This Replacement Option vests as follows: 8,864 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 2,700 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024. /s/ Robin Harper Cowie as Attorney-in-Fact for Kieran O'Kane 2023-07-26